This document together with the Policy and Procedure documents to which it refers describes and defines the Quality Management System of the Neuroimmunology & CSF Laboratory (NICL). It has been compiled to meet the requirements of the Clinical Pathology Accreditation (UK) Ltd. (CPA), ISO 15189:2012 (E) and other appropriate national and international standards.

<table>
<thead>
<tr>
<th>Review date</th>
<th>Reviewed by</th>
<th>Changes</th>
</tr>
</thead>
</table>
| July 2014   | VCW         | Requirements for patient consent added  
And HIV cognitive panel added to test list |
| March 2015  | MDC         | Added lactate, NfH, edited asialotransferrin storage,  
anti-recoverin TaT |

**Document cross-index**

The following documents should also be consulted in the context contained herein:

NICL-QMD-001_NICL_Quality manual
INDEX

STAFF STRUCTURE ........................................................................................................... 4
GENERAL INFORMATION .................................................................................................. 5
  Background ................................................................................................................... 5
  Access to services ........................................................................................................ 5
  Internal (NHNN) requests .......................................................................................... 5
POSTAL ADDRESS & CONTACTS .................................................................................. 6
SAMPLE HANDLING & TRANSPORTATION .................................................................... 6
  Special requirements for sample collection and handling ........................................... 6
PATIENT SAMPLE AND REQUEST FORM IDENTIFICATION CRITERIA ....................... 7
NICL TEST LIST .............................................................................................................. 8
  Routine CSF Analysis .................................................................................................. 8
  Oligoclonal Bands (IgG) .............................................................................................. 8
  Xanthochromia & Ferritin ......................................................................................... 8
  Total Tau-Protein & Amyloid Beta1-42 ....................................................................... 8
  Phospho-Tau .............................................................................................................. 8
  14-3-3 ....................................................................................................................... 9
  S100b ......................................................................................................................... 9
  Lactate ........................................................................................................................ 9
  Neurofilament heavy chain ....................................................................................... 9
  HIV CSF Cognitive Panel .......................................................................................... 9
  Asialotransferrin (Beta2-transferrin) .......................................................................... 10
  Anti-ACh Receptor Antibodies .................................................................................. 10
  Anti-Basal Ganglia Antibodies .................................................................................. 10
  Anti-Neuronal Antibodies ......................................................................................... 10
  Anti-Glycolipid Antibodies ....................................................................................... 10
  Anti-MAG Antibodies ............................................................................................... 11
  Anti-GAD Antibodies ............................................................................................... 11
  Anti-Recoverin Antibodies ....................................................................................... 11
  Anti-NMDA Receptor Antibodies ............................................................................. 11
  Neutralising Antibodies to b-Interferon ..................................................................... 11
  Vascular Endothelial Growth Factor ........................................................................ 11
  Transferrin Glycoforms ............................................................................................ 12
TURNAROUND TIMES ...................................................................................................... 13
SUGGESTIONS AND COMPLAINTS .............................................................................. 13
PATIENT CONSENT ........................................................................................................ 13
APPENDIX 1 .................................................................................................................... 14
  Testing for total tau protein and amyloid beta in CSF ............................................... 14
APPENDIX 2 .................................................................................................................... 15
  Testing for neutralising antibodies to interferon-beta in serum .................................. 15
**STAFF STRUCTURE**

**Neuroimmunology & CSF Laboratory**
**Queen Square Division**

**Clinical Lead**

*Dr MPT Lunn MBBS PhD FRCP*  
Consultant Neurologist

**Laboratory Manager**

*Dr VC Worthington BSc PhD CSci*  
Consultant Clinical Scientist

**Administration**

*Mrs JE Johnson*  
Office Manager

**Analytical**

*Position Vacant*  
Principal Clinical Scientist

*Dr AJ Church BSc PhD*  
Senior Biomedical Scientist

*Dr MD Chapman BSc MSc PhD*  
Senior Biomedical Scientist

*Ms D Grant BSc MA MSc*  
Biomedical Scientist

*Ms NJ Lakdawala BSc MSc*  
Biomedical Scientist

*Mr MKL Chou BSc*  
Biomedical Scientist

*Ms R Monero BSc MSc*  
Medical Technical Officer

*Mr THY Man BSc*  
Medical Laboratory Assistant
GENERAL INFORMATION

Background

The Neuroimmunology & CSF Laboratory (NICL) is a fully accredited (CPA UK) clinical consultant-led laboratory within the University College London Hospitals NHS Foundation Trust. It is located on the 9th Floor of the Institute of Neurology (IoN), next to the National Hospital for Neurology & Neurosurgery (NHNN) in Queen Square. The laboratory is part of the Queen Square Division within the Trust.

The laboratory provides an analytical service for the routine examination of cerebrospinal fluid (CSF) for the NHNN that includes triaging material between other laboratories within the Pathology Directorate. It forms a single point of contact for all work carried out on CSF within NHNN.

In addition, the laboratory provides specialist analytical services and associated clinical advice for referring laboratories throughout the United Kingdom and abroad with on-going research programmes supplementing and continuously enhancing the service provision. The NICL is dedicated to the analysis of CSF to aid in the diagnosis of neurological diseases such as inflammatory demyelinating disorders and dementia and also provides a specialist autoantibody service for immunological disorders affecting the central and peripheral nervous system.

Access to services

The Laboratory is open between the hours 9.00 – 17.00 Monday to Friday.

NOTE: The Laboratory does NOT operate an out-of-hours service

Please arrange in advance if a sample is to arrive in the lab after 4.30pm (020 3448 3814)

Internal (NHNN) requests

After 5pm CSF samples from NHNN are processed in the Whitfield St Labs (UCLH). The requesting Doctor must: Bleep the on-call Microbiology BMS in advance and arrange sample transport to Whitfield St.

- At 6.00pm there is a specimen pick-up at the NHNN basement Specimen Reception (Ext: 83198)
- From 7.00pm to midnight there is an hourly specimen pick-up from the NHNN front desk
- After midnight specimen transport is by the Medical Courier (0207 307 9383), a budget code will be needed to organise this.
POSTAL ADDRESS & CONTACTS

Address

Neuroimmunology & CSF Laboratory
Institute of Neurology (NHNN) Box 76
Queen Square
London WC1N 3BG

Telephone

020 3448 3814  Main laboratory  (General analytical and result enquiries)
020 3448 3812  Ms Jan Johnson  jan.johnson@uclh.nhs.uk  (Office Manager)
020 3448 4198  Dr Viki Worthington  viki.worthington@uclh.nhs.uk  (CDG, NAbs)
020 3448 3542  Dr Miles Chapman  miles.chapman@uclh.nhs.uk  (CSF biomarkers)
020 3448 3842  Dr Andrew Church  andrew.church@uclh.nhs.uk  (Autoantibodies)

Fax (safe haven)  020 3448 3797

SAMPLE HANDLING AND TRANSPORTATION

With the exception of samples for CSF biomarkers for neurodegeneration (see below), samples may be transported to the laboratory under normal postal regulations for the transport of pathological specimens (UN3373). We do not offer an out-of-hours service, therefore please post samples at the beginning of the week to avoid delays at weekends and bank holidays.

Special requirements for sample collection and handling

Serum: To help avoid haemolysis during transit all serum samples from external labs should be centrifuged and separated before sending.

Oligoclonal bands: A paired serum sample is essential for interpretation, preferably taken on same day (or within 14 days of the CSF). The CSF and serum should be sent together.

CSF biomarkers for neurodegeneration: CSF must be collected in polypropylene tubes (NOT polystyrene) then centrifuged, separated and the supernatant frozen in aliquots (one for each test required) preferably within one hour of the LP. The CSF must remain frozen and be transported to the NICL on dry ice. See Appendix 1. If in doubt please contact the laboratory viki.worthington@uclh.nhs.uk for advice before taking sample.

Xanthochromia: Supernatant from centrifuged CSF should be protected from light during storage and transport. (Annals of Clinical Biochem 2008; 45: 238-244). To aid result interpretation please note any deviations from protocol on the request form.

High risk samples: All high risk (e.g. HIV, Hep B, Hep C, CJD) specimens and the accompanying form must be clearly labelled and marked with biohazard stickers.
PATIENT SAMPLE AND REQUEST FORM IDENTIFICATION CRITERIA

It is the responsibility of the requester to ensure that samples are correctly labelled and that request forms are completed to the agreed standard.

The following outlines the information required by the Laboratory

Sample Tube

Essential
- Patient's full name or proper coded identifier
- Patient's date of birth
- Hospital (or NHS) number
- Date of sampling

Request Form

Essential
- Patient's full name or proper coded identifier
- Patient's date of birth
- Patient's hospital (or NHS) number
- Date of sampling
- Return address (hospital & department) for the report
- Tel. No. (& Bleep) for urgent results
- Tests required
- Sample type
- Relevant clinical details (to aid interpretation of results)

Desirable
- Patient's sex
- Name of the consulting physician

Patient's date of birth - Essential as the interpretation of some of tests is critically age-dependent.

Name of the consulting physician – Required for billing in some cases.

All details on both sample and request form must be completely legible. Specimens that are equivocally or illegibly labelled will not normally be accepted for analysis unless we receive written agreement from the Consulting Physician or Head of Department of the referral laboratory to accept full responsibility.
### NICL TEST LIST

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Sample Type</th>
<th>TaT</th>
<th>NHS Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Routine CSF Analysis</strong></td>
<td>CSF &amp; Serum</td>
<td>STAT</td>
<td>£59</td>
</tr>
<tr>
<td>Test for: Suspected CNS disease.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oligoclonal Bands (IgG)</strong></td>
<td>CSF &amp; Serum</td>
<td>7 working days</td>
<td>£45</td>
</tr>
<tr>
<td>Test for: Suspected CNS inflammation. Particularly demyelinating syndromes such as multiple sclerosis. Alternative name: OCB. Specimen requirements: Both CSF and a paired serum are essential for interpretation of results. CSF and blood samples will only be tested if they are taken within 14 days of each other. Minimum sample volume: 250μL in each tube. Special precautions/Transport: Samples should be unhaemolysed &amp; transported by first class post from outside NHNN. Methodology: Isoelectric focusing. EQA: UK NEQAS CSF IgG Oligoclonal Bands</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Xanthochromia &amp; Ferritin</strong></td>
<td>CSF</td>
<td>STAT</td>
<td>£58</td>
</tr>
<tr>
<td>Test for: Intracranial haemorrhage such as subarachnoid haemorrhage. Alternative name: Haem pigments. Specimen requirements: CSF in plain polypropylene tube. Minimum sample volume: 200μL. Special precautions/Transport: Samples should be unhaemolysed &amp; transported by first class post from outside NHNN. CSF must be protected from light to avoid bilirubin degradation (Annals of Clinical Biochem 2008; 45: 238-244). Methodology: Spectrophotometry and nephelometry for CSF ferritin. EQA: UK NEQAS CSF Haem Pigments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Tau-Protein &amp; Amyloid Beta1-42</strong></td>
<td>CSF</td>
<td>20 working days</td>
<td>£132</td>
</tr>
<tr>
<td>Test for: Investigation of dementias including Alzheimer’s Disease. Alternative name: Tau. Aβ1-42. CSF biomarkers for neurodegeneration for the investigation of cognitive impairment. Note: Elevation of total-tau is seen in several neurodegenerative conditions (including Alzheimer's disease) but also in stroke and encephalitides. Very high total tau levels are seen in diseases with rapid ongoing neuronal degeneration/destruction. Reduction in CSF Aβ1-42 is associated with deposition of β-amyloid in the brain, but has also been reported in neuroinflammatory conditions. Ratio of total tau:Aβ1-42 aids interpretation of results. Specimen requirements: CSF in plain polypropylene tube. Minimum sample volume: 500μL in separate polypropylene tubes for each test. Special precautions/Transport: Unhaemolysed CSF MUST be collected in polypropylene tubes, centrifuged, separated and the supernatant frozen on the same day as the LP. Samples from outside NHNN must be transported frozen on dry ice. For long term storage CSF must be kept frozen at -80°C. Important note: Aβ1-42 may be artificially low if samples are not processed correctly. See Appendix 1. Methodology: ELISA EQA: Alzheimer's Association EQA Scheme (European)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Phospho-Tau</strong></td>
<td>CSF</td>
<td>25 working days</td>
<td>£66</td>
</tr>
<tr>
<td>Test for: Investigation of dementias including Alzheimer’s Disease. Elevated phospho-tau levels indicate tangle pathology as seen in Alzheimer’s disease and are not usually seen in other conditions. Alternative name: P-Tau</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Name</td>
<td>Sample Type</td>
<td>TaT</td>
<td>NHS Price</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>14-3-3</strong></td>
<td>CSF</td>
<td>25 working days</td>
<td>£20</td>
</tr>
<tr>
<td>Test for: Investigation of neurodegenerative disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative name: CSF protein 14-3-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum sample volume: 500μL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special precautions/Transport: Unhaemolysed CSF MUST be collected in polypropylene tubes, centrifuged, separated and the supernatant frozen on the same day as the LP. Samples from outside NHNN must be transported frozen on dry ice. For long term storage CSF must be kept frozen at -80°C.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodology: ELISA EQA: Alzheimer’s Association EQA Scheme (European)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>S100b</strong></td>
<td>CSF</td>
<td>25 working days</td>
<td>£40</td>
</tr>
<tr>
<td>Test for: Investigation of neurodegenerative and neuroinflammatory disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative name: S100beta</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum sample volume: 500μL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special precautions/Transport: Unhaemolysed CSF MUST be collected in polypropylene tubes, centrifuged, separated and the supernatant frozen on the same day as the LP. Samples from outside NHNN must be transported frozen on dry ice. For long term storage CSF must be kept frozen at -80°C.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodology: Western Immunoblotting EQA: None available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lactate</strong></td>
<td>CSF</td>
<td>STAT</td>
<td>£5</td>
</tr>
<tr>
<td>Test for: Metabolic disturbance and possible infection.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum sample volume: 500μL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special precautions/Transport: Samples should be unhaemolysed &amp; transported by first class post from outside NHNN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodology: Enzymology EQA: UK NEQAS CSF Proteins and Biochemistry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurofilament heavy chain</strong></td>
<td>CSF</td>
<td>40 working days (under review)</td>
<td>£40</td>
</tr>
<tr>
<td>Test for: Investigation of neurodegenerative and neuroinflammatory disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative name: NfH, pNfH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minimum sample volume: 500μL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special precautions/Transport: Samples should be unhaemolysed &amp; transported by first class post from outside NHNN.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodology: ELISA EQA: None</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV CSF Cognitive Panel</strong></td>
<td>CSF</td>
<td>25 working days</td>
<td>£380</td>
</tr>
<tr>
<td>Test for: Investigation of cognitive decline in cases of HIV. Includes CSF biomarkers: Total tau. Aβ1-42, S100b. Ferritin. Neopterin. Specimen requirements: CSF in plain polypropylene tube. Minimum sample volume: 250-500μL in separate polypropylene tubes for each test. Special precautions/Transport: Unhaemolysed CSF MUST be collected in polypropylene tubes, centrifuged, separated and the supernatant frozen on the same day as the LP. Samples from outside NHNN must be transported frozen on dry ice. For long term storage CSF must be kept frozen at -80°C. Important note: Aβ1-42 may be artificially low if samples are not processed correctly. See Appendix 1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodology: Various</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Asialotransferrin (Beta2-transferrin)
- **Sample type:** Unknown fluid
- **TaT:** 6 working days
- **NHS Price:** £50

**Test for:** CSF leak in unknown fluids, for example in CSF rhinorrhea or otorrhea.
**Alternative name:** Tau transferrin. Also referred to as 'Tau'. However, this is **NOT** the same biomarker as tau-protein; the dementia biomarker (see above). To avoid confusion please do **NOT** use the term 'tau protein' when requesting this test.

**Specimen requirements:** Unhaemolysed fluid in a SMALL plain tube.
**Note:** Please do not use large containers for small fluid volumes as evaporation will lead to processing difficulties.
- **Minimum sample volume:** 100 μL.
- **Special precautions/Transport:** First class post. Please store frozen if not posting immediately.

**Methodology:** Electrophoresis or isoelectric focusing

**EQA:** UK NEQAS CSF Beta2 Transferrin

### Anti-ACh Receptor Antibodies
- **Sample type:** Serum
- **TaT:** 15 working days
- **NHS Price:** £20

**Test for:** Autoimmune Myasthenia Gravis
**Alternative name:** Acetylcholine receptor autoantibodies.

**Specimen requirements:** Serum
- **Minimum sample volume:** 500 μL.
**Special precautions/Transport:** Samples should be unhaemolysed & transported by first class post from outside NHNN
**Methodology:** ELISA

**EQA:** UK NEQAS Acetyl Choline Receptor Antibodies

### Anti-Basal Ganglia Antibodies
- **Sample type:** Serum
- **TaT:** 10 working days
- **NHS Price:** £68

**Test for:** Sydenham's chorea
**Alternative name:** ABGA
**Note:** Includes antibodies to enolase, pyruvate kinase, aldolase.

**Specimen requirements:** Serum
- **Minimum sample volume:** 500 μL.
**Special precautions/Transport:** Samples should be unhaemolysed & transported by first class post from outside NHNN
**Methodology:** Western Immunoblotting

**EQA:** None available

### Anti-Neuronal Antibodies
- **Sample type:** Serum
- **TaT:** 10 working days
- **NHS Price:** £40

**Test for:** Paraneoplastic neurological syndromes
**Alternative name:** PNS antibodies
**Note:** Includes antibodies to Hu, Yo, Ri, Ma1, Ma2, CV2, amphyphysin, Sox1, Tr, PCA2.
**With Zic4 and Gephyrin by prior arrangement.**

**Specimen requirements:** Serum
- **Minimum sample volume:** 500 μL.
**Special precautions/Transport:** Samples should be unhaemolysed & transported by first class post from outside NHNN
**Methodology:** Indirect immunofluorescence, Western and recombinant immunoblotting.

**EQA:** UK NEQAS for Paraneoplastic Antibodies

### Anti-Glycolipid Antibodies
- **Sample type:** Serum
- **TaT:** 10 working days
- **NHS Price:** £40

**Test for:** Autoimmune peripheral neuropathies
**Alternative name:** Anti-ganglioside antibodies.
**Routine screen:** Includes antibodies to GM1, GD1a, GD1b, GT1b, GQ1b
**Additional screen available on request (£40):** Includes antibodies to GA1, GM2, GM3, GD3, GT1a
**Sulphatides available on request (£20):** Antibodies to sulphatides

**Specimen requirements:** Serum
- **Minimum sample volume:** 500 μL.
**Special precautions/Transport:** Samples should be unhaemolysed & transported by first class post from outside NHNN
**Methodology:** ELISA

**EQA:** NEQAS Pilot Scheme
<table>
<thead>
<tr>
<th>Test</th>
<th>Sample type</th>
<th>TaT</th>
<th>NHS Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-MAG Antibodies</td>
<td>Serum</td>
<td>21 working days</td>
<td>£50</td>
</tr>
</tbody>
</table>
| Test for: Autoimmune neuropathies associated with myeloma and IgM paraprotein  
Alternative name: Anti-Myelin Associated Glycoprotein Antibodies  
Specimen requirements: Serum  
Minimum sample volume: 500μL.  
Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN  
Methodology: ELISA  
EQA: None available | | |
| Anti-GAD Antibodies | Serum | 10 working days | £40 |
| Test for: Autoimmune diabetes and autoimmune stiff person syndrome  
Alternative name: Anti-Glutamic Acid Decarboxylase Antibodies  
Specimen requirements: Serum  
Minimum sample volume: 500μL.  
Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN  
Methodology: ELISA  
EQA: UK NEQAS for Paraneoplastic Antibodies | | |
| Anti-Recoverin Antibodies | Serum | 40 working days | £68 |
| Test for: Paraneoplastic retinopathy  
Specimen requirements: Serum  
Minimum sample volume: 500μL.  
Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN  
Methodology: Western immunoblot  
EQA: None available | | |
| Anti-NMDA Receptor Antibodies | Serum | 10 working days | £40 |
| Test for: Autoimmune encephalitis  
Alternative name: Anti-N-methyl-D-aspartate receptor antibodies  
Specimen requirements: Serum  
Minimum sample volume: 500μL.  
Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN  
Methodology: Indirect immunofluorescence  
EQA: None available | | |
| Neutralising Antibodies to b-Interferon | Serum | 21 working days | £90 |
| Test for: Monitoring multiple sclerosis patients on beta-interferon therapy  
Alternative name: NAbs  
Note: Binding antibodies do not necessarily neutralise the bioactivity of beta-interferon. This bioassay measures antibodies that bind and neutralise beta-interferon activity.  
Specimen requirements: Serum  
Minimum sample volume: 500μL.  
Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN  
Methodology: Luciferase bioassay  
EQA: None available | | |
| Vascular Endothelial Growth Factor | Serum | 21 working days | £55 |
| Test for: POEMS syndrome and myeloma. POEMS: peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes.  
Alternative name: VEGF  
Specimen requirements: Serum  
Minimum sample volume: 500μL. | | |
### Transferrin Glycoforms

| Test for: | Congenital disorders of glycosylation (CDG). This is NOT a test for alcohol abuse or haemochromatosis. |
| Alternative name: | CDG screen |
| Note: | This test may be unreliable in neonates younger than three weeks due to the presence of maternal transferrin. Recent transfusion may invalidate the result. |
| Specimen requirements: | Serum |
| Minimum sample volume: | 500μL. |
| Special precautions/Transport: | Samples should be unhaemolysed & transported by first class post from outside NHNN |
| Methodology: | Isoelectric focusing |
| EQA: | ERNDIM CDG Scheme |

<table>
<thead>
<tr>
<th>Transferrin Glycoforms</th>
<th>Sample type: Serum</th>
<th>TaT: 9 working days</th>
<th>NHS Price: £50</th>
</tr>
</thead>
</table>

- Test for: Congenital disorders of glycosylation (CDG). This is NOT a test for alcohol abuse or haemochromatosis.
- Alternative name: CDG screen
- Note: This test may be unreliable in neonates younger than three weeks due to the presence of maternal transferrin. Recent transfusion may invalidate the result.
- Specimen requirements: Serum
- Minimum sample volume: 500μL.
- Special precautions/Transport: Samples should be unhaemolysed & transported by first class post from outside NHNN
- Methodology: Isoelectric focusing
- EQA: ERNDIM CDG Scheme
TURNAROUND TIMES

The target turnaround time is for 90% of tests requested and is given as the number of working days from receipt to result authorisation, it is the within laboratory TaT as postal delays are not taken into account. All urgent results (e.g. all xanthochromia and positive beta-2 transferrins) are relayed by telephone or fax (safe haven), if possible, prior to a hardcopy of the report being sent in the post.

NOTE: Prices quoted are for NHS requests; these are a guide only and may be subject to change in the future.

SUGGESTIONS AND COMPLAINTS

Suggestions about our service may be raised at any time with the Laboratory Manager viki.worthington@uclh.nhs.uk or when completing our annual user satisfaction survey. Suggestions will be discussed and evaluated at departmental meetings.

All complaints will be dealt with in compliance with the UCLH Complaints Policy. The Laboratory Manager will investigate and issue a response as soon as possible.

PATIENT CONSENT

For samples referred from outside the UCLH Trust it is a requirement that there is patient consent to disclose clinical information and family history to relevant healthcare professionals as required for the purposes of diagnosis and patient management. On receipt of a referred sample for testing, as part of the service agreement, the NICL assumes that this consent has been given.
APPENDIX 1

Testing for total tau protein and amyloid beta in CSF

Sample requirements:

Unhaemolysed CSF MUST be collected in polypropylene tubes, centrifuged, separated and
the supernatant frozen at -80°C on the same day of lumbar puncture.
Please freeze in separate aliquots for each test (in polypropylene tubes - minimum volume
0.5mL per tube).
Note: Results may be unreliable if polystyrene tubes are used.

Polypropylene Universal tube: e.g. Sarstedt Product code 63.9922.254.
Polypropylene sample tube: e.g. Elkay 021-4204-500. Lids are extra and can be bought in a
variety of colours. (We use yellow lids, Elkay 021-4800-506)

Sample transport:

Samples must be sent frozen, on dry ice (solid CO₂), preferably at the beginning of the week
to avoid delays at weekends and bank holidays. Samples need to arrive in
Neuroimmunology before 5 pm. The samples need to remain frozen until analysis.

For enquiries contact:

Dr Miles Chapman (Biomedical Scientist)
Tel: 020 3448 3542
Email: miles.chapman@uclh.nhs.uk

Dr Viki Worthington (Clinical Scientist)
Tel: 020 3448 4198
Email: viki.worthington@uclh.nhs.uk
APPENDIX 2

Testing for neutralising antibodies to interferon-beta in serum

Sample requirements:

For interferon-beta neutralising antibody testing we require a serum sample (1-2ml minimum), with cells removed.

Sending samples within the UK:

These may be sent at ambient temperature by first class post, preferably at the beginning of the week to avoid delays at weekends and bank holidays.

Sending samples from overseas:

These should be frozen and sent on dry ice (solid CO₂), preferably at the beginning of the week to avoid delays at weekends and bank holidays. Please notify Dr Viki Worthington by email in advance (see address below).

The following information should be included with each sample:

The name of the consultant.
The address (including department) to send the report to.
The basic demographics of the patient.
The type of interferon-beta product that the patient is receiving.
When interferon-beta therapy was started.

For enquiries contact:

Dr Viki Worthington (Clinical Scientist)
Tel: 020 3448 4198
Email: viki.worthington@uclh.nhs.uk